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The role of platelets and the clotting system in the ini-
tiation and progression of atherosclerosis has received
significant attention. Most importantly, platelets and
thrombosis playa pivotal role in the pathogenesis of the
acute coronary syndromes of unstable angina, myo-
cardial infarction and sudden death. In each stage of the
development of coronary artery disease, from the early
symptomatic stage through the growing lesion and finally
to the complicated plaque that results in the precipitation
of the acute coronary syndromes, platelets and the clot-
ting system serve as a common link among them.
Antithrombotic therapy aimed at halting the pro-
gression of these syndromes, preventing their occurrence
or even reversing them (such as in the early stages of
acute myocardial infarction), has provided exciting new
modalities to treat these disorders. The use of aspirin in
unstable angina in two well designed studies has clearly
Recent evidence suggests that platelets and thrombosis play
an important role in the progression of coronary artery dis-
ease as well as in the pathogenesis of the acute coronary
syndromes of unstable angina, myocardial infarction and
sudden death. Progression of the ubiquitous raised fatty
streaks in the coronary arteries and other vessels into an
atherosclerotic plaque may, in part, be mediated by platelets
and the clotting system. Most importantly, however. the
acute coronary syndromes are frequently precipitated by
events involving the formation of thrombus on a disrupted,
preexisting atherosclerotic plaque. With a better understand-
ing of the pathogenesis of these conditions, a new role for
antithrombotic therapy has emerged.
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shown a reduction in fatal as well as nonfatal cardiac
events compared with control groups not treated with
aspirin. Although demonstration of a benefit of antico-
agulant and antiplatelet therapy is difficult owing to a
low event rate of thrombotic events (low sensitivity) and
other nonthrombotic fatal events (low specificity) after
myocardial infarction, pooled results have shown a fa-
vorable effect with their use. The usefulness of throm-
bolytic therapy in the early stages of acute myocardial
infarction depends on the timing of initiation of therapy,
the severity of the residual stenosis and possible use of
agents that protect the ischemic myocardium.
Other potential therapies for the acute coronary syn-
dromes are also suggested. Further studies are in prog-
ress to establish the clinical benefits of antithrombotic
agents in acute coronary syndromes.
(J Am Coil CardioI1986;8:67B-75B)
Role of Platelets in Atherogenesis
Stages in development of coronary atherosclerosis.
The natural history of coronary atherosclerotic disease can
be divided into five stages (I). In stage I. benign raised
fatty streaks develop. These are found in most young persons
and do not lead to symptoms. If these raised plaques grow
(stage II), clinical symptoms of angina pectoris may de-
velop. This stage is accelerated by certain cardiac risk fac-
tors as well as by racial and geographic influences. If a
plaque undergoes a rapid change due to plaque rupture with
or without thrombus formation (stage III), unstable angina,
myocardial infarction or sudden death may be the result.
Over time, the thrombus formed in stage III becomes or-
ganized, leading to growth of the plaque and possibly further
symptoms of angina pectoris (stage IV). In stage V, in-
farcted myocardium resulting in significant ventricular dys-
function may predispose to ventricular arrhythmia and sud-
den death. The role of platelets and thrombosis is mainly
limited to the first three stages. Therefore, the benefit of
antithrombotic therapy should be geared to these areas.
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Coronary Atherosclerotic Disease
Figure 1. Scheme of the five stages of evolution
of coronary atherosclerotic disease. Early le-
sions (stage I) (lower left) tend to progress to a
growing lesion (stage II) (middle) in those pa-
lien" with so-called risk factors of atheroscle-
rotic disease. Some plaques may undergo rapid
changes with thrombus formation (stage III) and
subsequent fibrosis (stage IV) (upper right).
Finally, extensive occlusive coronary disease and
infarcted myocardium result in significant left
ventricular (LV) dysfunctIOn (stage V) (lower
right). (Modified with permission from Fuster
V, et al. [I ]. )
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Stages I and II: asymptomatic phase and stable angina
phase (Fig. 1, Table 1). Platelets can attach to the endo-
thelial surfaces of coronary arteries; that is, when the endo-
thelial surface becomes damaged, platelets that contact these
areas become attached. Branch points in the coronary ar-
teries are the site of rapid turbulent flow that can lead to
endothelial damage (2,3). Damaged endothelium exposes
collagen fibers and von Willebrand factor, a protein related
to factor VIII (4). Platelets that contact these areas become
firmly attached by a process of "pseudopod" formation (5).
Once attached to the vessel wall, the platelets release plate-
let-derived growth factor, which stimulates smooth muscle
cells in the vascular intima to proliferate and which, in part,
are responsible for the synthesis of collagen and uptake of
cholesterol. This may ordinarily serve as a repair process,
but in the coronary arteries, can contribute to atherosclerotic
plaque development (6) of stages I and II. As mentioned,
von Willebrand factor is responsible for platelets contacting
injured endothelium to become firmly attached. The im-
portance of von Willebrand factor in this stage is supported
by a breeding colony of pigs with absence of von Willebrand
factor that is resistant to both spontaneous and high cho-
lesterol diet-induced atherosclerosis (7,8). There is no an-
tiplatelet drug currently available that can completely pre-
vent the adherence and activation of this single layer of
platelets. If a drug was developed that totally inhibited plate-
let adhesion, the risk of bleeding might preclude its long-
term use.
Stage III: acute and subacute coronary syndromes
(Fig. 1, Table 1). In stage III, the atherosclerotic plaque
undergoes a rapid change, which is due to plaque rupture
with or without thrombus formation (l). Why does this
occur? Sites of advanced atherosclerotic plaques are con-
tinuously undergoing bending and twisting movements. In
addition, these advanced plaques often have become rela-
tively soft owing to the buildup of fats beneath their fibrous
cap. Moreover, shear stresses or vasotonicity at the level
of stenosis may act on the softened lesions, predisposing
them to rupture or ulceration, exposing underlying collagen
and promoting thrombus formation. The clinical result may
be unstable angina, myocardial infarction or sudden death,
Table 1. Simplified Unified Concept of
Probable Sequential Events in Coronary
Atherosclerotic Disease: Role of Platelets and
Thrombosis in Stages I, II and III
Stage I
Early lesion,-a,ymptomatlc ,tage
Hemodynamic factor,-endothellal damage
Platelet deposition
Smooth muscle cell migratIOn and proliferation
Connective tls,ue syntheSIS
Lipid transformation and deposition
Stage II
Growing leSIon-angina pectow,
Progression of above (,low process)
Organization of thrombus (rapid process)*
Stage III
Complicated plaques (that IS, plaque rupture)
Un,table angina-thrombosis
Myocardial infarction-thrombotic occlusion*
Ischemic ,udden death
Myocardial infarction-thrombosis*
Myocardial ischemia
?Microemboli
*Events that may be prevented or dimmished by use
of antithrombotic therapy. Bold face type 10dicates step,
10 whIch platelets and thrombosis playa role.
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depending on the degree of obstruction caused by the throm-
bus and the duration and suddenness of the obstruction.
A Common Link Among the Acute
Coronary Syndromes
Plaque rupture and thrombus formation are important in
the pathogenesis of the acute coronary syndromes; that is,
there is evidence that the syndromes of unstable angina,
myocardial infarction, and sudden death all share in the
same pathophysiologic process (1,9, 10).
Unstable angina. Moise et al. (II) found progression
of coronary lesions in the majority of patients with unstable
angina undergoing coronary angiography as compared with
a smaller percentage in patients who had stable angina.
Similarly, Ambrose et al. (12) showed progression of coro-
nary stenoses in 76% of patients with repeat coronary an-
giography after the development of crescendo angina com-
pared with 33% of patients who had repeat angiography
with little or no change in symptoms. It has also been noted
that patients with unstable angina are more likely to have a
specific morphologic pattern of the coronary lesion con-
sisting of an eccentric stenosis with irregular borders or a
narrow neck, or both (13). Similar-appearing irregular le-
sions have been confirmed by pathologic examination to
represent disrupted atherosclerotic plaques or partially oc-
clusive thrombi, or both (14). Therefore, sudden progres-
sion in coronary stenoses as well as the development of a
morphologically distinct pattern may represent the disrup-
tion of an atherosclerotic plaque with thrombus formation
in patients with unstable angina.
Myocardial infarction. DeWood et al. (15) showed that
in the early hours after myocardial infarction, 87% of the
infarct-related arteries are totally occluded. In a subgroup
of patients who underwent emergency surgical revascular-
ization, thrombus was retrieved from the coronary arteries
in 88%. Reperfusion studies (16,17) have shown that throm-
bolytic therapy is effective in restoring perfusion to totally
occluded infarct-related arteries in 60 to 90% of patients.
Ambrose et al. (18) also showed that in patients with acute
myocardial infarction with less than 100% occluded arteries
or in patients receiving thrombolytic therapy with reperfu-
sion of a totally occluded artery, the same eccentric and
irregular-appearing coronary lesions seen in unstable angina
are found in the majority of patients.
Sudden death. Although a lethal arrhythmia is consid-
ered to be the terminal event in patients with sudden death,
there is evidence from patients surviving an episode of sud-
den death that myocardial infarction or ischemia is involved
in nearly two-thirds of patients (19,20). In addition, in two-
thirds of patients dying suddenly, pathologic evidence of
plaque rupture and thrombus formation is found (21). Re-
current, layered mural thrombi overlying the plaque with
or without peripheral embolization are also seen (22).
Antithrombotic Therapy for the Acute
Coronary Syndromes
From the previous discussion, clinical and pathologic
evidence suggests that thrombus formation occurring at the
site of a disrupted atherosclerotic plaque is a mechanism
linking the acute coronary syndromes. Therapy aimed at
preventing, limiting or dissolving the thrombus implicated
in these syndromes has recently gained interest (Table I).
Antithrombotic therapy can be based on the use of platelet
inhibitors, heparin, oral anticoagulants and thrombolytic
agents. We will review the role of antithrombotic therapy
in each of the clinical entities that make up the acute coro-
nary syndromes.
Unstable Angina
Aspirin. Aspirin therapy has an antiplatelet effect owing
to its acetylation of the cyclooxygenase enzyme in platelets.
Inhibition of this enzyme prevents formation of thrombox-
ane A2 (23). Because this inhibition is irreversible, restor-
ation of platelet function depends on release of new platelets
into the circulation. Therefore, aspirin has a sustained an-
tiplatelet effect. The use of antithrombotic therapy in un-
stable angina has been demonstrated by two randomized,
placebo-controlled double-blind trials (24,25) involving the
use of aspirin.
Veterans Administration Cooperative Study (24). This
randomized, placebo-controlled, double-blind clinical trial
was designed to determine if aspirin could decrease the
incidence of death and acute myocardial infarction in pa-
tients with unstable angina. The treated patients received
324 mg of aspirin in buffered solution (Alka-Seltzer) daily
for 12 weeks; the control patients received the buffer without
aspirin. From 1974 to 1981, the study of 1,266 men hos-
pitalized with unstable angina was conducted at 12 Veterans
Administration medical centers. To qualify for the study, a
patient had to have unstable angina beginning within I month
before and still present within the week before hospital
admission, evidence of coronary artery disease and no base-
line evidence of acute myocardial infarction. Unstable an-
gina was defined as new onset or worsening of angina,
manifested by frequency of one or more episodes per day,
duration longer than 15 minutes or occurrence at rest or
during minimal activity. Coronary arteriograms were not
performed routinely. Patients were entered into the study
within 51 hours of admission to the hospital.
During the 12 week treatment period. death or acute
myocardial infarction occurred in 10.1% of the placebo-
treated and 5.0% of the aspirin-treated patients (p = 0.00(5).
Acute myocardial infarction and nonfatal acute myocardial
infarction exhibited similar percent reductions with com-
parable p values. Death occurred in 3.3% of the placebo-
treated and 1.6% of the aspirin-treated patients (p = 0.54).
This difference was not statistically significant. However,
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the 51 % reduction in mortality in the aspirin group was the
same as that for acute myocardial infarction. Importantly,
follow-up study at 1 year showed persistence of the bene-
ficial effects of 12 weeks of aspirin therapy, with mortality
still 43% less in the aspirin-treated patients (p = 0.008).
The protective effects of aspirin treatment in unstable angina
appeared to be additive to any effect of beta-adrenergic
blocker therapy that may have been present.
There was no evidence of gastrointestinal side effects
from the study medicine. The occurrence of epigastric symp-
toms, hemoglobin decrease or occult blood in the stool at
any time during follow-up was equally distributed between
the treatment groups. Only 1.3% of the patients were with-
drawn from study because of possible treatment side effects,
and they were equally distributed between the placebo and
aspirin groups. The lack of gastrointestinal adverse effects
is probably a result of both the low dose of aspirin and its
administration in a buffered solution.
Canadian Multicenter Trial (25). The Canadian Multi-
center Trial of aspirin or sulfinpyrazone, or both, in unstable
angina was conducted in seven centers between 1979 and
1984. A total of 555 patients (73% men) entered the study,
and after a mean follow-up of 18 months, there was a marked
benefit from aspirin in the reduction of death and myocardial
infarction. Sulfinpyrazone conferred no benefit.
The target population consisted of patients admitted to a
coronary care unit with a clinical (nonangiographic) diag-
nosis of unstable angina. These patients underwent a de-
tailed interview to determine whether there was good clinical
or electrocardiographic evidence of myocardial ischemia
and whether there was an unstable pain pattern, either cres-
cendo pain or prolonged pain at rest. The study criteria were
satisfied by 85% of the 817 patients interviewed after the
exclusion process, among whom 159 refused study entry,
leaving 555 who entered the trial. Patients were randomly
allocated to one of four treatment regimens: aspirin (325
mg four times a day) or matching placebo, plus sulfinpyr-
azone (200 mg four times a day) or matching placebo, for
a total of eight tablets daily to be taken with meals or milk.
Coronary angiography was not a prerequisite for study entry.
However, it was performed at least once in 61 % of patients,
most often within the first 3 months of study entry. Coronary
artery lesions with stenoses of at least 50% of luminal di-
ameter were present in one vessel in 16% of patients, in
two vessels in 24%, in three vessels in 44% and in the left
coronary artery in 6%; such lesions were absent in 9%.
The primary analysis was to be one of efficacy, with
outcome to be assessed only among patients who met certain
criteria established at inception of the study and to be applied
without knowledge of the treatment allocated or of clinical
outcome. It was also decided in the design phase to report
the outcome in every randomized patient, following an "in-
tention to treat" approach. The outcome of greatest im-
portance was considered to be that of the combined total of
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Figure 2. Efficacy of aspirin (ASAl versus no aspirin in reducing
cardiac death or nonfatal myocardial infarction in patients with
unstable angina. (Reproduced with permiSSIOn from Cairns lA, et
al. [25].)
cardiac death and nonfatal myocardial infarction. It was also
planned to evaluate cardiac death alone and death from any
cause as important secondary outcomes. In the efficacy anal-
ysis, the primary outcome event of cardiac death or nonfatal
myocardial infarction occurred in 53 patients. There was no
overall benefit from sulfinpyrazone and no interaction with
aspirin. Accordingly, in Figure 2, we have depicted a
lifetable cumulative risk according to aspirin allocation. There
were 36 events in the groups not given aspirin, and 17 in
those taking aspirin, and by 2 years, the lifetable rate of
these events was 17% versus 8.6%, representing a risk re-
duction of 50.8% (p = 0.008). The outcome event of car-
diac death alone (Fig. 3) occurred in 22 patients not taking
aspirin, and in 6 given aspirin, and by 2 years, the lifetable
rate of these events was 11.7% versus 3%, representing a
risk reduction of 71 % (p = 0.004). All deaths were cardiac
in this analysis.
In the intention to treat analysis, counting all randomized
patients and all outcomes, the outcome of cardiac death or
nonfatal myocardial infarction was observed in 70 patients,
including 17 patients who were excluded from the primary
Figure 3. Efficacy of aspirin (ASA) versus no aspirin in reducing
cardiac death in patients with unstable angina. (Reproduced with
permission from Cairns lA, et al. [25].)
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analysis of efficacy. Again, sulfinpyrazone had no signifi-
cant effect and no interaction with aspirin. The risk reduction
with aspirin was 30% (p = 0.072). With outcomes of car-
diac death and death from any cause, the corresponding risk
reductions with aspirin were 56.3% (p = 0.009) and 43.4%
(p = 0.035), respectively.
Gastrointestinal side effects occurred in 39% ofpatients
and were 29% more common among the patients receiving
aspirin. However, most of these were minor, including ab-
dominal discomfort, indigestion, nausea, vomiting and con-
stipation. Only seven patients had either occult blood in the
stool, rectal bleeding or melena (one of these requiring
transfusion), and eight had peptic ulcer. These potentially
dangerous gastrointestinal side effects, observed in only 3%
of patients, were not more common among those receiving
aspirin, although among those receiving neither aspirin nor
sulfinpyrazone, only one patient had such a complication.
Differences in the studies. The greater protective effect
of aspirin in the Veterans Administration Cooperative Study
(24) and the Canadian Multicenter Trial (25) compared with
the several trials after myocardial infarction is probably
related to several differences. Patients with unstable angina
often have an acute, potentially reversible thrombus (high
specificity), and the frequency of complicating thrombotic
clinical events in the form of myocardial infarction and
sudden death is high (high sensitivity). Thus, when treated
acutely, a patient with unstable angina has a greater potential
for benefit than does a patient with a myocardial infarction
in whom, as described later, the frequency of recurrent
clinical events is low (low sensitivity) and some of the
recurrent events such as sudden death related to myocardial
dysfunction are not thrombotic (low specificity). Although
most of the patients in these studies were men, the results
of the Canadian study suggest that the conclusions hold true
for women as well.
Heparin and oral anticoagulants. Intravenous heparin
therapy was shown to reduce the morbidity and mortality
in a small group of patients with the intermediate coronary
syndrome randomized to placebo, atenolol, heparin or a
combination of heparin and atenolol (26). There was an
80% reduction in mortality or acute myocardial infarction
in the heparin-treated group during the study period as com-
pared with the control group. This benefit was continued
for 8 weeks of follow-up. In addition, studies using intra-
venous heparin therapy followed by oral anticoagulant ther-
apy have also been reported (27,28). A beneficial effect in
terms of morbidity and mortality was seen in patients who
received anticoagulant therapy. However, all of these stud-
ies on heparin alone or heparin followed by oral anticoag-
ulants had either a large number of exclusions from the
study or from analysis or were not properly randomized and
controlled so that their conclusions may not be valid.
Thrombolytic therapy. The use of thrombolytic therapy
for unstable angina has been studied by several investiga-
tors. In patients with recent onset of severe unstable angina,
streptokinase was given into the coronary artery responsible
for the anginal syndrome at the time of catheterization (29).
There was an improvement of the coronary lesions in terms
of percent stenosis as compared with prestreptokinase per-
cent stenosis. In another study (30), streptokinase was given
by intravenous infusion over a period of 24 hours to a group
of patients with unstable angina and was followed by oral
anticoagulant therapy. This group was compared with a
similar group that received oral anticoagulants alone. There
was a statistically significant reduction in the incidence of
myocardial infarction at 6 months in the streptokinase group
compared with the group receiving only oral anticoagulants.
These studies, however, were done in a small number of
very selected patients. Therefore, the role of thrombolytic
therapy in unstable angina is still uncertain.
Myocardial Infarction
In assessing the benefit of antithrombotic therapy in myo-
cardial infarction, it must be emphasized that the risk of
dying from infarction is greatest immediately after the onset
of symptoms. The risk decreases over a period of days and
remains somewhat elevated for the first 6 months after the
infarction, Deaths occurring immediately after the onset of
symptoms are usually caused by arrhythmias, Deaths that
occur somewhat later are usually a result of pump failure.
Beyond 6 months, pump failure may also be a significant
cause of death. Because most deaths are not caused by
thrombotic events in the early phases at least, it is unlikely
that antithrombotic therapy would have much impact at this
stage. Thus, death is a nonspecific end point for thrombotic
events. In addition, reinfarction tends to occur with a low
incidence in the early phases after myocardial infarction.
Thus, the large number of patients needed to reach a valid
conclusion because of the low incidence of reinfarction makes
studies of antithrombotic therapy insensitive.
Oral anticoagulation. Despite the preceding consider-
ations, the pathologic evidence combined with the results
of a number of trials that were poorly designed by today's
criteria led to the widespread use of short-term anticoagulant
therapy for patients with myocardial infarction in the 1950s
and 1960s. However, three large studies (Medical Research
Council, Bronx Municipal, and Veterans Administration
(31-33) reduced the enthusiasm for the short-term therapy.
These studies failed to show the value of short-term anti-
coagulant therapy, and the treatment thereafter fell into dis-
favor.
The relatively low intensity of anticoagulation in these
trials has been stressed by Loeliger (34). Most patients
underwent anticoagulant therapy to a point now considered
appropriate for venous thrombosis (35), but not believed to
be adequate for arterial thrombosis. This may have con-
tributed to the poor results of the therapy. Other factors may
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have made interpretation of the results difficult, such as the
use of heparin therapy initially or the late initiation of ther-
apy (up to 72 hours from the onset of symptoms).
Long-term anticoagulant therapy. Therapeutic trials as-
sessing the role of anticoagulant therapy beyond 6 months
are more specific for possible thrombotic events. However,
the event rate is low and, therefore, these studies have a
low sensitivity. Three large studies (36-38) have assessed
the benefit of long-term anticoagulant therapy given after
myocardial infarction. While there seemed to be some re-
duction in mortality early on, there was no significant benefit
over follow-up periods of 2 to 7 years. However, if the
results of several studies are pooled (39), it appears that
long-term anticoagulant therapy may be protective against
recurrent infarction. In addition, the Dutch Sixty-Plus Rein-
farction Study (40) showed a significant reduction in myo-
cardial infarction and total mortality in patients older than
60 years of age. The greater benefit using anticoagulants in
this trial over previous trials may be related to two factors
in the Dutch trial: I) anticoagulant therapy was more rigidly
controlled, and 2) randomization into treatment groups was
made at a median of 6 years after a previous myocardial
infarction. Therefore, in this relatively stable group of pa-
tients, thrombotic events rather than myocardial factors dic-
tated long-term prognosis so that the specificity for throm-
bosis was higher.
Platelet inhibitors (Table 2). Anticoagulant therapy is
relatively dangerous and exposes the patient to a significant
risk of bleeding. More recently, drugs with antiplatelet ef-
fects that have been studied in patients recovering from
myocardial infarction include aspirin, sulfinpyrazone and
dipyridamole. It is unlikely that sulfinpyrazone or dipyr-
idamole has a significant role in the long-term therapy of
acute myocardial infarction. The discussion over the An-
turane Reinfarction Trial (41) had clouded the use of sul-
finpyrazone, and it is becoming unlikely that dipyridamole
has a significant antiplatelet effect on other than artificial
vascular surfaces. Eight large studies have been performed
with aspirin (or aspirin combined with dipyridamole) in
doses of 300 to 1,500 mg/day. These studies, when pooled
(42), suggest that aspirin reduces the rate of reinfarction by
21 %. There is also a significant reduction in death rate of
Table 2. Comparison of Platelet-Inhibitmg Drugs After Myocardial Infarction in Eight Prospective Randomized, Double-Blind
Placebo-Controlled Trials
Time
Between MI Duration of
and Entry Follow-Up Dosage Total No. Results
Tnal (Reference) (mean mol (mean mol Drug (mg/day) Patients Therapy End Point(s)
Elwood et al. (50) 2 V3 12 ASA 300 1,239 Favorable Total mortality
trend
Coronary Drug 3 22 ASA 927 1,529 Favorable Total and CAD
Project (51) trend mortality. MI
and other CY
events
Breddin et al. (38) I V3 24 ASA. 1,500 946 Favorable SD, MI (fatal and
phenoprocoumon trend nonfatal)
(Liquamar)
Elwood and V. 12 ASA 900 1,682 Favorable Total mortality
Sweetnam (52) trend
AMIS (53) 25 38 ASA 1,000 4,524 No benefit Total and CAD
mortality, MI
stroke
Paris (53) 20 41 ASA 972 2.026 Favorable Total and CAD
trend mortality, CAD
incidence
ASA + D 972 + 225 Favorable Total and CAD
trend mortality, CAD
mcidence
ART(4\) 16 Sulf 800 1,558 Decreased Total and CAD
SD only mortality, CAD
incidence
ARIS (55) 2/3 19 Sulf 800 727 Decreased MI, SD, CAD
MIonly total mortality
PARIS (56) 2 23 ASA + D 972 + 225 3,128 Decreased Total and CAD
all end mortality. MI,
points CAD incidence
AMIS = Aspirm Myocardial Infarction Study; ARIS = Anturane Reinfarction italian Study; ART = Anturane Reinfarction Trial; ASA = aspmn;
CAD = coronary artery disease; D = dipyridamole; MI = myocardial infarction; SD = sudden death; Sulf = sulfinpyrazone
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the same magnitude as with the pooled results of antico-
agulant therapy (39). Given the low risk of the lower dosage
of aspirin used, a case can be made for its use as the preferred
antithrombotic drug after acute myocardial infarction.
Thrombolytic therapy. There has been much recent
interest in thrombolytic therapy initiated within the first few
hours after the onset of acute myocardial infarction. Strep-
tokinase has been given to patients intravenously as well as
directly into the infarct-related coronary artery at the time
of catheterization performed immediately after the diagnosis
of myocardial infarction was made. The procedure often
recanalizes totally occluded vessels (16). Tissue-type plas-
minogen activator, a naturally occurring protease that has
the ability to specifically dissolve fibrin clots, has also been
used to recanalize acutely occluded vessels of patients within
the first few hours after the onset of acute myocardial in-
farction (43).
Factors in clinical outcome. Although successful reca-
nalization of the infarct-related arteries has been shown to
occur after thrombolytic therapy, the practical utility of this
therapy depends on limitation of infarct size with preser-
vation of ventricular function and a decrease in mortality.
Spontaneous recanalization can occur. Therefore, the clin-
ical end points of improvement in ventricular function and
mortality are the ones most often studied. Several factors
play a key role in the clinical outcome of thrombolytic
therapy. These factors are the timing of initiation of therapy,
the severity of the residual stenosis and the evolving concept
of myocardial protection.
The importance ofearly initiation oftherapy is borne out
in a recent placebo-controlled trial performed in Italy (44),
using intravenous streptokinase given to patients within 12
hours of the onset of acute myocardial infarction. The study
group comprised nearly 12,000 patients. The results of the
trial showed that hospital mortality was 10.7% in strepto-
kinase recipients versus 13% in control patients (Table 3).
This significant reduction in mortality was more striking as
a function of time from onset of pain to streptokinase in-
fusion. Table 3 shows that the extent of reduction in mor-
tality was greatest in those patients receiving streptokinase
less than 3 hours from the onset of pain.
Table 3. Mortality by Hours From Onset of Symptoms to
Streptokinase or Placebo Therapy
MortalIty (%)
Improvement in I year mortality after thrombolysis was
shown in a trial by Simoons et al. (45), in which strepto-
kinase was given within 4 hours from the onset of chest
pain. The I year survival rate in the treated group was 91 %
compared with a survival rate of 84% in the conventionally
treated group. Ventricular function also appears to be pre-
served if thrombolytic therapy is initiated soon after the
onset of symptoms. The study by Koren et al. (46), using
early (average 1.7 hours) administration of intravenous
streptokinase often initiated in a mobile care unit, showed
a significantly higher left ventricular ejection fraction in the
treated group (56%) than in the control group (47%). The
Intravenous Streptokinase in Acute Myocardial Infarction
(ISAM) Study (47) also showed a preservation of global
and regional ejection fractions in patients treated with in-
travenous streptokinase within 6 hours of the onset of
symptoms.
The importance of residual stenosis is demonstrated by
the Western Washington Trial (48). The 1 year survival rate
in this study was only improved in a subset of patients who
achieved complete recanalization with normal or nearly nor-
mal distal coronary flow. Those patients with p;rrtial reper-
fusion and, therefore, more severe residual stenoses had a
mortality rate similar to that in patients without reperfusion.
Further evidence to support the importance of residual ste-
nosis has been shown in a study by O'Neill et al. (49).
Patients undergoing successful coronary angioplasty within
12 hours of the onset of acute myocardial infarction had
greater improvement in ventricular function than did those
treated with thrombolysis alone. The residual stenosis after
angioplasty (43%) was significantly less than that in patients
receiving streptokinase (83%).
Modalities that protect ischemic myocardium. Finally,
there is interest in attempting to increase the amount of
salvageable myocardium by modalities that protect the isch-
emic myocardium. Drugs such as calcium antagonists or
beta-blockers may delay the point beyond which irreversible
myocardial damage occurs. The second phase of the Throm-
bolysis in Myocardial Infarction Trial (TIMI II) will study
the possible benefits of metoprolol, given to a subset of
patients, on the 1 year mortality rate and left ventricular
function. The role of thrombolytic therapy in acute myo-
cardial infarction, therefore, depends on early initiation of
therapy, achievement of complete reperfusion with minimal
residual stenosis and, perhaps, the ability to protect the
ischemic myocardium.
NS = not SIgnificant.
<3 9.2
3t06 11.7
6 to 9 12.6
9 to 12 15.8
Total (0 to 12) 10.7
Hours Streptokinase Control
12.0
14.1
14.1
13.6
13
p
00005
0.03
NS
NS
0.0002
Sudden Death
In many cases of sudden death, the cause can be attributed
to a rapidly progressive atherosclerotic plaque that under-
goes disruption with thrombus formation. Patients dying
soon after the onset of unstable angina are found to have a
ruptured plaque and evidence of mural thrombosis with or
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without microemboli or microinfarcts, or both, distal to the
thrombosis (21,22). The reduction in sudden death previ-
ously discussed in patients receiving antithrombotic therapy
for unstable angina is evidence for its potential use. In trials
using anticoagulants for secondary prevention after myo-
cardial infarction, as mentioned previously, sudden death
occurring soon after infarction is more likely related to myo-
cardial dysfunction. Therefore, these trials lack the neces-
sary specificity to show beneficial result.
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